Efficacy and Safety of Camrelizumab Plus Apatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR or ALK Genetic Aberration.

Guanghui Gao,Jian Ni,Yina Wang,Shengxiang Ren,Zhihua Liu,Gongyan Chen,Kangsheng Gu,Aimin Zang,Jun Zhao,Renhua Guo,Jianxing He,Xiaoyan Lin,Yueyin Pan,Zhiyong Ma,Zhehai Wang,Min Fan,Yunpeng Liu,Shundong Cang,Xinfeng Yang,Weixia Li,Quanren Wang,Caicun Zhou

DOI: https://doi.org/10.21037/tlcr-22-22

2022-01-01

Translational Lung Cancer Research

Abstract:Background: Camrelizumab plus apatinib shows encouraging antitumor activity and acceptable toxicity in chemotherapy-pretreated patients with advanced non-small cell lung cancer (NSCLC), however, clinical benefits from this combination regimen in NSCLC patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) have not been reported. We assessed the efficacy and safety of this combined regimen in pretreated patients with advanced NSCLC and defined EGFR/ALK status (EGFR+/ ALK+) in a phase lb/2 trial. Methods: Previously treated patients with advanced EGFR+/ALK+ NSCLC were enrolled and given camrelizumab 200 mg intravenously every 2 weeks plus apatinib at the recommended dose of 250 mg orally once daily. Patients harboring sensitive EGFR mutations or ALK fusion genes had received at least one EGFR/ALK TKI and a platinum-based chemotherapy regimen before the enrollment. The primary endpoint was objective response rate (ORR). Results: All 43 enrolled patients comprised the efficacy and safety analysis population. The confirmed ORR was 18.6% (95% CI: 8.4-33.4) and the dinical benefit response rate was 27.9% (95% CI: 15.3-43.7). Median progression-free survival (PFS) was 2.8 months (95% CI: 1.9-5.5) and median overall survival was not reached (95% CI: 7.3-not reached), with a median follow-up period of 15.7 months (range, 0.5-24.4). The most common grade >= 3 treatment-related adverse events (TRAEs) were hypertension (16.3%), proteinuria (11.6%) and palmar-plantar erythrodysaesthesia syndrome (9.3%). No unexpected adverse events were recorded. Conclusions: Camrelizumab plus apatinib showed moderate antitumor activity and acceptable safety profile in previously treated patients with advanced NSCLC and EGFR or ALK genetic aberrations, which warranted further validation.